Budget Cuts Threaten Research on Antimicrobial Resistance

Share this content:
Budget Cuts Threaten Research on Antimicrobial Resistance
Budget Cuts Threaten Research on Antimicrobial Resistance

THURSDAY, Sept. 7, 2017 (HealthDay News) -- Proposed budget cuts could seriously hamper efforts to address antimicrobial resistance (AMR), according to an article published online Sept. 4 in the Annals of Internal Medicine.

Helen W. Boucher, M.D., from Tufts Medical Center in Boston, and colleagues discussed the impact that proposals by the Trump administration could have on efforts to combat the threat of increasing resistance to antimicrobial agents.

The authors write that the president's budget request, released in May, would reduce the U.S. Centers for Disease Control and Prevention's AMR funding by 14 percent and place it within the Prevention and Public Health Fund, which the administration is seeking to repeal. The budget would also cut National Institute of Allergy and Infectious Diseases funding, reducing development of new antimicrobial drugs, diagnostics, and vaccines. In addition, a proposed 51 percent cut to the U.S. Agency for International Development's global health programs would drastically impair the agency's ability to support antimicrobial stewardship and infection prevention.

"Over the past two years, our nation's health experts and leaders have worked diligently to enable the United States to tackle AMR head-on. If now enacted, these proposed budget cuts would reverse this course, which would go against the widespread agreement of experts and be to the detriment of our nation," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »